20 results on '"Pinelli D"'
Search Results
2. Heterogeneously catalyzed ammoximation of cyclohexanone with molecular oxygen in vapor phase
- Author
-
Collina, D., primary, Pieri, E., additional, Pinelli, D., additional, Trifirò, F., additional, Petrini, G., additional, and Paparatto, G., additional
- Published
- 1993
- Full Text
- View/download PDF
3. Heterogeneous catalytic ammoximation of cyclohexanone with ammonia and molecular oxygen
- Author
-
Busca, G., primary, Giamello, E., additional, Pinelli, D., additional, and Trifirò, F., additional
- Published
- 1993
- Full Text
- View/download PDF
4. On The Bifuntional Nature Of Gas-Phase Cyclohexanone Ammoximation Catalyst
- Author
-
Dreoni, D.P., primary, Pinelli, D., additional, and Trifiro, F., additional
- Published
- 1992
- Full Text
- View/download PDF
5. Redox Dynamics and Structure/Activity Relationships in Vanadium-Oxide on TiO2 Catalyst
- Author
-
Centi, G., primary, Granados, M.Lopez, additional, Pinelli, D., additional, and Trifiro', F., additional
- Published
- 1991
- Full Text
- View/download PDF
6. Synthesis of Phthalic and Maleic Anhydrides from n-Pentane: Reactivity of Possible Intermediates and co-Feeding Experiments
- Author
-
Centi, G., primary, Pinelli, D., additional, Trifiro, F., additional, Ungarelli, F., additional, and Nieto, J. Lopez, additional
- Published
- 1990
- Full Text
- View/download PDF
7. Contemporaneous Insertion of O and N on Hydrocarbons by Heterogeneous Catalysis: Synthesis of Imides by Ammoxidation
- Author
-
Cavani, F., primary, Centi, G., additional, Pinelli, D., additional, Trifiro, F., additional, and Nieto, J.Lopez, additional
- Published
- 1988
- Full Text
- View/download PDF
8. Contemporaneous insertion of oxygen and nitrogen on hydrocarbons by heterogeneous catalysis: synthesis of imides by ammoxidation
- Author
-
Cavani, F., Centi, Gabriele, Lopez, N. J., Pinelli, D., and Trifiro, F.
- Subjects
vanadium oxide catalyst ammoxidn titanium oxide catalyst ammoxidn ammoxidn butene butane mechanism maleimide butane ammoxidn phthalimide xylene ammoxidn - Published
- 1988
9. Fairness and pitfalls of the Italian waiting list for elective liver transplantation: The ECALITA registry study.
- Author
-
Manzia TM, Trapani S, Nardi A, Ricci A, Lenci I, Sensi B, Angelico R, De Feo TM, Agnes S, Andorno E, Baccarani U, Carraro A, Cescon M, Cillo U, Colledan M, Pinelli D, De Carlis L, De Simone P, Ghinolfi D, Benedetto FD, Ettorre GM, Gruttadauria S, Lupo LG, Tandoi F, Mazzaferro V, Romagnoli R, Rossi G, Caccamo L, Rossi M, Spada M, Vennarecci G, Vivarelli M, Zamboni F, Tisone G, Cardillo M, and Angelico M
- Abstract
Background: The challenge of transplant waiting-lists is to provide organs for all candidates while maintaining efficiency and equity., Aims: We investigated the probability of being transplanted or of waiting-list dropout in Italy., Methods: Data from 12,749 adult patients waitlisted for primary liver-transplantation from January 2012 to December 2022 were collected from the National Transplant-Registry.The cohort was divided into Eras:1 (2012-2014);2 (2015-2018);and 3 (2019-2022)., Results: The one-year probability of undergoing transplant increased (67.6 % in Era 1vs73.8 % in Era 3,p < 0001) with a complementary 46 % decrease in waiting-list failures. Patients with hepatocellular-carcinoma were transplanted more often than cirrhotics[at model for end-stage liver-disease (MELD)-15:HR = 1.28,95 %CI:1.21-1.35;at MELD-25:HR = 1.04,95 %CI:0.92-1.19) and those with other indications (at MELD-15:HR = 1.27,95 %CI:1.11-1.46) across all eras. Candidates with Hepatitis-B-virus (HBV)related disease had a greater probability of transplant than those with Hepatitis-C virus-related (HR = 1.13,95 %CI:1.07-1.20), alcohol-related (HR = 1.13,95 %CI:1.05-1.21), and metabolic-related (HR = 1.18,95 %CI:1.09-1.28)disease. Waiting-list failures increased by 27 % every 5 MELD-points and by 14 % for every 5-year increase in recipient-age and decreased by 10 % with each 10-cm increase in stature. Blood-group O patients showed the highest probability of waiting-list failure (HR = 1.28,95 %CI:1.15-1.43)., Conclusions: Liver-transplantation waiting-list success-rates have significantly improved in Italy, with patients with hepatocellular-carcinoma and/or HBV-related diseases being favored. High MELD-score, old-age, short-stature, and blood-group O were significant risk-factors for waiting-list failure. Efforts to improve organ-allocation and prioritization-policies are underway., Competing Interests: Conflict of interest The authors of this manuscript have no conflicts of interest to disclose., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Development and validation of an adsorption process for phosphate removal and recovery from municipal wastewater based on hydrotalcite-related materials.
- Author
-
Maggetti C, Pinelli D, Di Federico V, Sisti L, Tabanelli T, Cavani F, and Frascari D
- Abstract
In the current international context characterized by the tendency to stricter limits for P concentration in treated wastewater and a strong drive towards phosphate recovery, it is crucial to develop cost-effective technologies to remove and recover phosphate from municipal wastewater (MWW). In this study, an initial screening of the phosphate adsorption performances of 9 sorbents including several hydrotalcites led to the selection of calcined pyroaurite - an innovative material composed of mixed Mg/Fe oxides - as the best-performing one. The assessment of calcined pyroaurite by means of isotherms and continuous-flow adsorption/desorption tests conducted with actual MWW resulted in a high P sorption capacity (12 mg
P g-1 at the typical phosphate concentration in MWW), the capacity to treat 730 BVs at the 1 mgP L-1 breakpoint imposed by the current EU legislation, and a 93 % phosphate recovery. Calcined pyroaurite resulted in satisfactory performances also in a test conducted with a saline MWW deriving from a hotspot of seawater intrusion, a rapidly increasing phenomenon as a result of climate change. Five consecutive adsorption/desorption cycles conducted in a 20-cm column at a 5-min empty bed contact time resulted stable in terms of P adsorption/recovery performances, specific surface area and chemical structure of calcined pyroaurite. In the perspective to apply phosphate recovery with calcined pyroaurite at full scale, the process scale-up to a 60-cm packed bed - close to the column heights of industrial applications - resulted in stable performances. Calcium phosphate, widely used to produce phosphate-based fertilizers, can be obtained from the desorbed product by precipitation with Ca(OH)2 . These results point to calcined pyroaurite as a very promising material for phosphate removal and recovery from MWW and from other P-rich effluents in a circular economy perspective., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
11. Living Donor Lung Transplantation After Hematopoietic Stem Cell Transplantation From the Same Donor: A Risk Worth Taking.
- Author
-
Camagni S, D'Antiga L, Di Marco F, Grazioli L, Bonanomi E, Pinelli D, Beretta M, Tintori V, Lucianetti A, and Colledan M
- Subjects
- Humans, Child, Living Donors, Immunosuppression Therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Lung Transplantation
- Abstract
Living donor (LD) lung transplantation (LT) represents an exceptional procedure in Western countries. However, in selected situations, it could be a source of unique advantages, besides addressing organ shortage. We report a successful case of father-to-child single-lobe LT, because of the complications of hematopoietic stem cell transplantation from the same donor, with initial low-dose immunosuppressive therapy and subsequent early discontinuation. Full donor chimerism was hypothesized to be a mechanism of transplant tolerance, and this postulated immunological benefit was deemed to outweigh the risks of living donation and the possible drawbacks of single compared with bilateral LT. Favorable size matching and donor's anatomy, accurate surgical planning, and specific expertise in pediatric transplantation also contributed to the optimal recipient and donor outcomes. Ten months after LD LT, the patient's steadily good lung function after withdrawal of immunosuppressive therapy seems to confirm the original hypothesis., Competing Interests: Financial/Nonfinancial Disclosures None declared, (Copyright © 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion.
- Author
-
Camagni S, Amaduzzi A, Grazioli L, Ghitti D, Pasulo L, Pinelli D, Fagiuoli S, and Colledan M
- Subjects
- Humans, Organ Preservation methods, Perfusion adverse effects, Perfusion methods, Liver surgery, Graft Survival, Warm Ischemia adverse effects, Tissue Donors
- Abstract
Background: Livers from controlled donation after circulatory death (cDCD) with very prolonged warm ischemic time (WIT) are regularly transplanted after abdominal normothermic regional perfusion (aNRP) plus ex-situ machine perfusion (MP). Considering aNRP as in-situ MP, we investigated whether the results of a pilot experience of extended criteria cDCD liver transplantation (LT) with prolonged WIT, with aNRP alone, were comparable to the best possible outcomes in low-risk cDCD LT., Methods: Prospectively collected data on 24 cDCD LT, with aNRP alone, were analyzed., Results: The median total and asystolic WIT were 51 and 25 min. Measures within benchmark cut-offs were: median duration of surgery (5.9 h); median intraoperative transfusions (3 units of red blood cells); need for renal replacement therapy (2/24 patients); median intensive care stay (3 days); key complications; overall morbidity, graft loss, and retransplantation up to 12 months; 12-month mortality (2/21 patients). The median hospital stay (33 days, due to logistics) and mortality up to 6 months (2/24 patients, due to graft-unrelated causes) exceeded benchmark thresholds., Conclusions: This pilot experience suggests that livers from cDCD with very prolonged WIT that appear viable during adequate quality aNRP may be safely transplanted, with no need for ex-situ MP, with considerable resource savings., (Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Improving outcomes of in situ split liver transplantation in Italy over the last 25 years.
- Author
-
Lauterio A, Cillo U, Spada M, Trapani S, De Carlis R, Bottino G, Bernasconi D, Scalamogna C, Pinelli D, Cintorino D, D'Amico FE, Spagnoletti G, Miggino M, Romagnoli R, Centonze L, Caccamo L, Baccarani U, Carraro A, Cescon M, Vivarelli M, Mazaferro V, Ettorre GM, Rossi M, Vennarecci G, De Simone P, Angelico R, Agnes S, Di Benedetto F, Lupo LG, Zamboni F, Zefelippo A, Patrono D, Diviacco P, Laureiro ZL, Gringeri E, Di Francesco F, Lucianetti A, Valsecchi MG, Gruttadauria S, De Feo T, Cardillo M, De Carlis L, Colledan M, and Andorno E
- Subjects
- Humans, Treatment Outcome, Retrospective Studies, Liver, Tissue Donors, Graft Survival, Italy epidemiology, Liver Transplantation methods
- Abstract
Background & Aims: Split liver transplant(ation) (SLT) is still considered a challenging procedure that is by no means widely accepted. We aimed to present data on 25-year trends in SLT in Italy, and to investigate if, and to what extent, outcomes have improved nationwide during this time., Methods: The study included all consecutive SLTs performed from May 1993 to December 2019, divided into three consecutive periods: 1993-2005, 2006-2014, and 2015-2019, which match changes in national allocation policies. Primary outcomes were patient and graft survival, and the relative impact of each study period., Results: SLT accounted for 8.9% of all liver transplants performed in Italy. A total of 1,715 in situ split liver grafts were included in the analysis: 868 left lateral segments (LLSs) and 847 extended right grafts (ERGs). A significant improvement in patient and graft survival (p <0.001) was observed with ERGs over the three periods. Predictors of graft survival were cold ischaemia time (CIT) <6 h (p = 0.009), UNOS status 2b (p <0.001), UNOS status 3 (p = 0.009), and transplant centre volumes: 25-50 cases vs. <25 cases (p = 0.003). Patient survival was significantly higher with LLS grafts in period 2 vs. period 1 (p = 0.008). No significant improvement in graft survival was seen over the three periods, where predictors of graft survival were CIT <6 h (p = 0.007), CIT <6 h vs. ≥10 h (p = 0.019), UNOS status 2b (p = 0.038), and UNOS status 3 (p = 0.009). Retransplantation was a risk factor in split liver graft recipients, with significantly worse graft and patient survival for both types of graft (p <0.001)., Conclusions: Our analysis showed Italian SLT outcomes to have improved over the last 25 years. These results could help to dispel reservations regarding the use of this procedure., Impact and Implications: Split liver transplant(ation) (SLT) is still considered a challenging procedure and is by no means widely accepted. This study included all consecutive in situ SLTs performed in Italy from May 1993 to December 2019. With more than 1,700 cases, it is one of the largest series, examining long-term national trends in in situ SLT since its introduction. The data presented indicate that the outcomes of SLT improved during this 25-year period. Improvements are probably due to better recipient selection, refinements in surgical technique, conservative graft-to-recipient matching, and the continuous, yet carefully managed, expansion of donor selection criteria under a strict mandatory split liver allocation policy. These results could help to dispel reservations regarding the use of this procedure., (Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial).
- Author
-
Sposito C, Pietrantonio F, Maspero M, Di Benedetto F, Vivarelli M, Tisone G, De Carlis L, Romagnoli R, Gruttadauria S, Colledan M, Agnes S, Ettorre G, Baccarani U, Torzilli G, Di Sandro S, Pinelli D, Caccamo L, Sartore Bianchi A, Spreafico C, Torri V, and Mazzaferro V
- Subjects
- Humans, Prospective Studies, Disease-Free Survival, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Liver Transplantation, Colorectal Neoplasms pathology, Liver Neoplasms drug therapy, Liver Neoplasms surgery
- Abstract
Background: Patients with unresectable Colorectal Liver Metastases (CLM) receiving palliative chemotherapy have a 5-year overall survival (OS) of less than 30%. Liver transplantation (LT) can improve OS up to 60%-83% (SECA-I and SECA-II trials). The aim of the study is to assess the efficacy of LT in liver-only metastatic CRC compared with a matched cohort of patients included in a phase III trial on triplet chemotherapy + antiEGFR., Patients and Methods: The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial (ClinicalTrials.gov NCT03803436). Hyperselected patients with liver-limited unresectable CLM, RAS and BRAF wild-type and curatively removed primary colon cancer are included. The observed post-transplant outcomes will be prospectively compared 1:5 with those obtained in a matched cohort from the TRIPLETE trial (NCT03231722)., Results: Primary endpoint is to compare the 3 and 5-years OS of patients enrolled in the COLT trial with COLT-eligible population enrolled in the TRIPLETE trial. An expected gain in OS of 40% at 5-years is predicted for the COLT population (the expected OS at 5-years in COLT vs. TRIPLETE is 70% vs. 30%). Secondary endpoints are to compare the 5-years disease-free survival and to assess the safety of LT (Dindo-Clavien Classification and the Comprehensive Complication Index)., Conclusion: LT offers the longest OS reported in selected patients with CLM. Improving the selection strategies can give patients a 5-year OS similar to other indications for LT and a better outcome than those undergoing chemotherapy alone., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series.
- Author
-
Pinelli D, Micalef A, Merelli B, Trezzi R, Amaduzzi A, Agnesi S, Guizzetti M, Camagni S, Fedele V, and Colledan M
- Subjects
- Female, Humans, Combined Modality Therapy, Prognosis, Neoadjuvant Therapy, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Pancreatic Neoplasms surgery, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal surgery
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) becomes a systemic disease from an early stage. Complete surgical resection remains the only validated and potentially curative treatment; disappointingly only 20% of patients present with a resectable tumour. Although a complete pathological regression (pCR) after the preoperative chemotherapy could intuitively lead to better outcomes and prolonged survival some reports highlighted significant rates of recurrence., Cases Presentation: We describe three cases of pCR following preoperative chemotherapy for PDAC. The first two cases received neoadjuvant mFOLFIRINOX and PAX-G scheme for borderline resectable PDAC. Recurrence appeared 9 and 12 months after surgery. Although both patients started adjuvant therapy straight after the diagnosis of recurrence, the disease rapidly progressed and led them to death 12 and 15 months after surgery. The third case was characterized by germline BRCA2 mutation. The patient presented with PDAC of the body, intrapancreatic biliary stenosis and suspected peritoneal metastasis. One year later, after first and second-line chemotherapy, she underwent explorative laparoscopy and total spleno-pancreatectomy without evidence of viable tumour cells in the surgical specimen. At six months she is recurrence-free., Conclusions: Very few reports describe a complete pathological response following preoperative chemotherapy in pancreatic cancer. We observed three cases in the last three years with disappointing oncological results. Further investigations are needed to predict PDAC prognosis in pCR after chemotherapy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.
- Author
-
Pinelli DF, Wakeman BS, Wagener ME, Speck SH, and Ford ML
- Subjects
- Animals, CD8-Positive T-Lymphocytes drug effects, Drug Therapy, Combination, Herpesviridae Infections immunology, Immunosuppressive Agents adverse effects, Immunosuppressive Agents pharmacology, Mice, Sirolimus pharmacology, Abatacept adverse effects, CD8-Positive T-Lymphocytes immunology, CTLA-4 Antigen immunology, Gammaherpesvirinae, Herpesviridae Infections drug therapy, Immunosuppressive Agents therapeutic use, Sirolimus therapeutic use
- Abstract
Latent viral infections are a major concern among immunosuppressed transplant patients. During clinical trials with belatacept, a CTLA4-Ig fusion protein, patients showed an increased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder, thought to be due to a deficient primary CD8(+) T cell response to the virus. Using a murine model of latent viral infection, we observed that rapamycin treatment alone led to a significant increase in virus-specific CD8(+) T cells, as well as increased functionality of these cells, including the ability to make multiple cytokines, while CTLA4-Ig treatment alone significantly dampened the response and inhibited the generation of polyfunctional antigen-specific CD8(+) T cells. However, the addition of rapamycin to the CTLA4-Ig regimen was able to quantitatively and qualitatively restore the antigen-specific CD8(+) T cell response to the virus. This improvement was physiologically relevant, in that CTLA4-Ig treated animals exhibited a greater viral burden following infection that was reduced to levels observed in untreated immunocompetent animals by the addition of rapamycin. These results reveal that modulation of T cell differentiation though inhibition of mTOR signaling can restore virus-specific immune competence even in the absence of CD28 costimulation, and have implications for improving protective immunity in transplant recipients., (© Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2015
- Full Text
- View/download PDF
17. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig.
- Author
-
Pinelli DF, Wagener ME, Liu D, Yamniuk A, Tamura J, Grant S, Larsen CP, Suri A, Nadler SG, and Ford ML
- Subjects
- Abatacept, Animals, CD40 Antigens immunology, CD40 Antigens metabolism, CD40 Ligand immunology, CD8-Positive T-Lymphocytes immunology, Cytokines metabolism, Humans, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Ovalbumin physiology, Skin Transplantation, T-Lymphocytes, Regulatory metabolism, T-Lymphocytes, Regulatory pathology, Tissue Donors, Transplantation, Homologous, Antibodies, Monoclonal pharmacology, CD40 Ligand antagonists & inhibitors, Forkhead Transcription Factors metabolism, Graft Survival immunology, Immunoconjugates pharmacology, Immunosuppressive Agents pharmacology, T-Lymphocytes, Regulatory immunology
- Abstract
The use of monoclonal antibodies targeting the CD154 molecule remains one of the most effective means of promoting graft tolerance in animal models, but thromboembolic complications during early clinical trials have precluded their use in humans. Furthermore, the role of Fc-mediated deletion of CD154-expressing cells in the observed efficacy of these reagents remains controversial. Therefore, determining the requirements for anti-CD154-induced tolerance will instruct the development of safer but equally efficacious treatments. To investigate the mechanisms of action of anti-CD154 therapy, two alternative means of targeting the CD40-CD154 pathway were used: a nonagonistic anti-CD40 antibody and an Fc-silent anti-CD154 domain antibody. We compared these therapies to an Fc-intact anti-CD154 antibody in both a fully allogeneic model and a surrogate minor antigen model in which the fate of alloreactive cells could be tracked. Results indicated that anti-CD40 mAbs as well as Fc-silent anti-CD154 domain antibodies were equivalent to Fc-intact anti-CD154 mAbs in their ability to inhibit alloreactive T cell expansion, attenuate cytokine production of antigen-specific T cells and promote the conversion of Foxp3(+) iTreg. Importantly, iTreg conversion observed with Fc-silent anti-CD154 domain antibodies was preserved in the presence of CTLA4-Ig, suggesting that this therapy is a promising candidate for translation to clinical use., (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2013
- Full Text
- View/download PDF
18. Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass.
- Author
-
Corno V, Dezza MC, Lucianetti A, Codazzi D, Carrara B, Pinelli D, Parigi PC, Guizzetti M, Strazzabosco M, Melzi ML, Gaffuri G, Sonzogni V, Rossi A, Fagiuoli S, and Colledan M
- Subjects
- Adult, Humans, Intraoperative Period, Liver Failure etiology, Lung Diseases etiology, Male, Treatment Outcome, Cardiopulmonary Bypass, Cystic Fibrosis complications, Cystic Fibrosis surgery, Liver Failure surgery, Liver Transplantation methods, Lung Diseases surgery, Lung Transplantation methods
- Abstract
Sequential bilateral single lung-liver transplantation (SBSL-LTx) is a therapeutic option for patients with end stage lung and liver disease (ESLLD) due to cystic fibrosis (CF). A few cases have been reported, all of them were performed with the use of cardio-pulmonary by-pass (CPB). We performed SBSL-LTx in three young men affected by CF. All the recipients had respiratory failure and portal hypertension with hypersplenism. Along with lung transplants, two patients received a whole liver graft and one an extended right graft from an in situ split liver. During transplantation neither CPB nor veno-venous by-pass (VVB) were employed. Immunosuppression was based on basiliximab, tacrolimus, steroids and azathioprine. The three recipients are alive with a median follow-up of 670 days (range 244-1,533). Combined SBSL-LTx is a complex but effective procedure for the treatment of ESLLD due to CF, not necessarily requiring the use of CPB or VVB.
- Published
- 2007
- Full Text
- View/download PDF
19. Long-term aerobic cometabolism of a chlorinated solvent mixture by vinyl chloride-, methane- and propane-utilizing biomasses.
- Author
-
Frascari D, Pinelli D, Nocentini M, Zannoni A, Fedi S, Baleani E, Zannoni D, Farneti A, and Battistelli A
- Subjects
- Aerobiosis, Biodegradation, Environmental, Biomass, Colony Count, Microbial methods, Hydrocarbons, Chlorinated chemistry, RNA, Ribosomal, 16S analysis, RNA, Ribosomal, 16S genetics, Soil Pollutants chemistry, Solvents chemistry, Temperature, Time Factors, Hydrocarbons, Chlorinated metabolism, Methane pharmacology, Propane pharmacology, Soil Pollutants metabolism, Solvents metabolism, Vinyl Chloride pharmacology, Water Pollutants, Chemical metabolism
- Abstract
The aerobic cometabolic biodegradation of a mixture of chlorinated aliphatic hydrocarbons (CAHs) including vinyl chloride (VC), cis- and trans-1,2-dichloroethylene (cis-DCE, trans-DCE), trichloroethylene (TCE), 1,1,2-trichloroethane (1,1,2-TCA) and 1,1,2,2-tetrachloroethane (1,1,2,2-TeCA) was investigated at both 25 and 17 degrees C by means of bioaugmented and non-bioaugmented sediment-groundwater slurry microcosm tests. The goals of the study were (i) to study the long-term aerobic biodegradation of a CAH mixture including a high-chlorinated solvent (1,1,2,2-TeCA) generally considered non-biodegradable in aerobic conditions; (ii) to investigate the efficacy of bioaugmentation with two types of internal inocula obtained from the indigenous biomass of the studied site; (iii) to identify the CAH-degrading bacteria. VC, methane and propane were utilized as growth substrates. The non-bioaugmented microcosms were characterized, at 25 degrees C, by an average 18-day lag-time for the direct metabolism of VC (accompanied by the cometabolism of cis- and trans-DCE) and by long lag-times (36-264 days) for the onset of methane or propane utilization (associated with the cometabolism of the remaining CAHs). In the inoculated microcosms the lag-phases for the onset of growth substrate utilization and CAH cometabolism were significantly shorter (0-15 days at 25 degrees C). Biodegradation of the 6-CAH mixture was successfully continued for up to 410 days. The low-chlorinated solvents were characterized by higher depletion rates. The composition of the microbial consortium of a propane-utilizing microcosm was determined by 16s rDNA sequencing and phylotype analysis. To the best of our knowledge, this is the first study that documents the long-term aerobic biodegradation of 1,1,2,2-TeCA.
- Published
- 2006
- Full Text
- View/download PDF
20. Hormonal modulation of Ishikawa cells during three-dimensional growth in vitro.
- Author
-
Pinelli DM, Drake J, Williams MC, Cavanagh D, and Becker JL
- Subjects
- Estradiol pharmacology, Estrogen Antagonists pharmacology, Female, Humans, Megestrol Acetate pharmacology, Progesterone pharmacology, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Tamoxifen pharmacology, Tumor Cells, Cultured, Cell Culture Techniques methods, Endometrial Neoplasms pathology, Hormones pharmacology
- Abstract
Objectives: The Ishikawa endometrial cancer cell line is hormonally responsive, expressing estrogen and progesterone receptors (ER, PR) when grown in traditional monolayer culture. The purpose of this paper is to demonstrate a three-dimensional spheroid culture system for cancer cells. We used this system to determine the response of the Ishikawa cell line to estradiol-17 beta (E), tamoxifen (T), megestrol acetate (MA), and progesterone (P)., Methods: Ishikawa cells were incubated in polyurethane culture bags using phenol red-free media containing ethanol (0.1%, controls), E (1 mumol, or 1 nmol), T (1 mumol, or 10 nmol), MA (1 mumol, or 10 nmol), or P (1 mumol). Cellular morphology was assessed by hematoxylin and eosin staining, and expression of estrogen and progesterone receptors was determined immunohistochemically using an immunoperoxidase technique., Results: Cells in control cultures demonstrated minimal organization and lacked hormone receptors. In contrast, cells exposed to either E or T displayed significant glandular formation, with multicellular, microvilli-rich, columnar epithelia exhibiting polarized nuclear arrangements. Within 4 weeks, E- and T-treated cultures showed upregulated nuclear staining for PR, with little ER present. Cells treated with MA or P showed less glandular organization but expressed ER with PR downregulation., Conclusions: These data support the use of this novel three-dimensional culture system to study the modulation of tumor cell biologic activity in response to hormonal agents. Future applications of this model include examining in vitro responsiveness of cancer cell lines to additional biologic agents and chemotherapeutic regimens.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.